Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) has been given a $23.00 price objective by investment analysts at Cantor Fitzgerald in a research note issued to investors on Wednesday. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. Cantor Fitzgerald’s price target would indicate a potential upside of 62.54% from the company’s previous close.

The analysts wrote, “Valeant announced that the FDA confirmed it intends to issue a Voluntary Action Indicated (VAI) inspection classification for its Bausch + Lomb manufacturing facility in Tampa, Florida.””

A number of other research firms also recently weighed in on VRX. BMO Capital Markets restated a “hold” rating and issued a $15.00 price target on shares of Valeant Pharmaceuticals International in a research note on Thursday, July 27th. Zacks Investment Research upgraded shares of Valeant Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a research note on Thursday, July 27th. J P Morgan Chase & Co set a $10.00 price target on shares of Valeant Pharmaceuticals International and gave the company a “hold” rating in a research note on Monday, July 17th. Deutsche Bank AG set a $19.00 price target on shares of Valeant Pharmaceuticals International and gave the company a “hold” rating in a research note on Monday, July 17th. Finally, Stifel Nicolaus restated a “buy” rating and issued a $35.00 price target on shares of Valeant Pharmaceuticals International in a research note on Friday, June 30th. Four analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. Valeant Pharmaceuticals International currently has a consensus rating of “Hold” and an average target price of $17.31.

Valeant Pharmaceuticals International (NYSE VRX) opened at 14.15 on Wednesday. The company has a 50-day moving average of $16.35 and a 200 day moving average of $13.38. The company’s market cap is $4.93 billion. Valeant Pharmaceuticals International has a one year low of $8.31 and a one year high of $32.74.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last released its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 EPS for the quarter, beating the consensus estimate of $0.97 by $0.08. Valeant Pharmaceuticals International had a negative net margin of 12.40% and a positive return on equity of 59.89%. The firm had revenue of $2.23 billion for the quarter, compared to analyst estimates of $2.23 billion. During the same period last year, the firm earned ($0.88) EPS. The business’s quarterly revenue was down 7.7% compared to the same quarter last year. Equities research analysts predict that Valeant Pharmaceuticals International will post $3.89 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Valeant Pharmaceuticals International, Inc. (VRX) Given a $23.00 Price Target at Cantor Fitzgerald” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/08/16/cantor-fitzgerald-reiterates-buy-rating-for-valeant-pharmaceuticals-international-inc-vrx.html.

Hedge funds have recently added to or reduced their stakes in the stock. Gruss & Co. Inc. bought a new stake in Valeant Pharmaceuticals International during the first quarter valued at $104,000. Financial Architects Inc raised its stake in Valeant Pharmaceuticals International by 18.6% in the first quarter. Financial Architects Inc now owns 9,550 shares of the specialty pharmaceutical company’s stock valued at $105,000 after buying an additional 1,500 shares in the last quarter. Harbor Advisors LLC bought a new stake in Valeant Pharmaceuticals International during the first quarter valued at $110,000. NEXT Financial Group Inc raised its stake in Valeant Pharmaceuticals International by 6.2% in the second quarter. NEXT Financial Group Inc now owns 10,303 shares of the specialty pharmaceutical company’s stock valued at $178,000 after buying an additional 600 shares in the last quarter. Finally, WMS Partners LLC bought a new stake in Valeant Pharmaceuticals International during the first quarter valued at $116,000. Institutional investors own 50.96% of the company’s stock.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.